Targeting Stat3 in cancer therapy.

Stat3 is constitutively activated in many human cancers where it functions as a critical mediator of oncogenic signaling through transcriptional activation of genes encoding apoptosis inhibitors (e.g. Bcl-x(L), Mcl-1 and survivin), cell-cycle regulators (e.g. cyclin D1 and c-Myc) and inducers of angiogenesis (e.g. vascular endothelial growth factor). This article reviews several approaches that have been pursued for targeting Stat3 in cancer therapy including antisense strategies, tyrosine kinase inhibition, decoy phosphopeptides, decoy duplex oligonucleotides and G-quartet oligodeoxynucleotides (GQ-ODN). The GQ-ODN strategy is reviewed in somewhat greater detail than the others because it includes a novel system that effectively delivers drug into cells and tissues, addresses successfully the issue of specificity of targeting Stat3 versus Stat1, and has demonstrated efficacy in vivo.

[1]  M. Groudine,et al.  Control of c-myc regulation in normal and neoplastic cells. , 1991, Advances in cancer research.

[2]  A. Patel,et al.  myc function and regulation. , 1992, Annual review of biochemistry.

[3]  C. Thompson,et al.  bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death , 1993, Cell.

[4]  J. Darnell,et al.  Stat3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6. , 1994, Science.

[5]  S. Akira,et al.  Molecular cloning of APRF, a novel IFN-stimulated gene factor 3 p91-related transcription factor involved in the gp130-mediated signaling pathway , 1994, Cell.

[6]  P. Heinrich,et al.  The interleukin-6-activated acute-phase response factor is antigenically and functionally related to members of the signal transducer and activator of transcription (STAT) family , 1994, Molecular and cellular biology.

[7]  C. Thompson,et al.  bcl-XL is the major bcl-x mRNA form expressed during murine development and its product localizes to mitochondria. , 1994, Development.

[8]  C. Schindler,et al.  Association of transcription factor APRF and protein kinase Jak1 with the interleukin-6 signal transducer gp130. , 1994, Science.

[9]  J. Ihle.  Cytokine receptor signalling , 1995, Nature.

[10]  Min Zhang,et al.  Metabolic Engineering of a Pentose Metabolism Pathway in Ethanologenic Zymomonas mobilis , 1995, Science.

[11]  J. Darnell,et al.  Transcriptional responses to polypeptide ligands: the JAK-STAT pathway. , 1995, Annual review of biochemistry.

[12]  R. Jove,et al.  Enhanced DNA-binding activity of a Stat3-related protein in cells transformed by the Src oncoprotein. , 1995, Science.

[13]  J. Blenis,et al.  Requirement of serine phosphorylation for formation of STAT-promoter complexes. , 1995, Science.

[14]  M. Kaplan,et al.  Impaired IL-12 responses and enhanced development of Th2 cells in Stat4-deficient mice , 1996, Nature.

[15]  E. Furth,et al.  Liver Failure and Defective Hepatocyte Regeneration in Interleukin-6-Deficient Mice , 1996, Science.

[16]  A. Levitzki,et al.  Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor , 1996, Nature.

[17]  J. Stephens,et al.  The Expression and Regulation of STATs during 3T3-L1 Adipocyte Differentiation (*) , 1996, The Journal of Biological Chemistry.

[18]  T. Hirano,et al.  Two signals are necessary for cell proliferation induced by a cytokine receptor gp130: involvement of STAT3 in anti-apoptosis. , 1996, Immunity.

[19]  J. Darnell,et al.  Transcriptionally active Stat1 is required for the antiproliferative effects of both interferon alpha and interferon gamma. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[20]  J. Darnell.  STATs and gene regulation. , 1997, Science.

[21]  R. Craig,et al.  Mcl-1, a Bcl-2 family member, delays the death of hematopoietic cells under a variety of apoptosis-inducing conditions. , 1997, Blood.

[22]  T. Hirano,et al.  Involvement of STAT3 in the Granulocyte Colony-stimulating Factor-induced Differentiation of Myeloid Cells* , 1997, The Journal of Biological Chemistry.

[23]  S. Akira,et al.  Targeted disruption of the mouse Stat3 gene leads to early embryonic lethality. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[24]  C. Justicia,et al.  Stat3 Is Present in the Developing and Adult Rat Cerebellum and Participates in the Formation of Transcription Complexes Binding DNA at the sis‐Inducible Element , 1997, Journal of neurochemistry.

[25]  S. Becker,et al.  Three-dimensional structure of the Stat3β homodimer bound to DNA , 1998, Nature.

[26]  J. Turkson,et al.  Stat3 Activation by Src Induces Specific Gene Regulation and Is Required for Cell Transformation , 1998, Molecular and Cellular Biology.

[27]  L. M. Facchini,et al.  The molecular role of Myc in growth and transformation: recent discoveries lead to new insights , 1998, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[28]  A. Chong,et al.  IFN-gamma induces cell growth inhibition by Fas-mediated apoptosis: requirement of STAT1 protein for up-regulation of Fas and FasL expression. , 1998, Cancer research.

[29]  D. Tweardy,et al.  Stat3 and G-CSF-induced myeloid differentiation. , 1998, Leukemia & lymphoma.

[30]  R. Jove,et al.  Activation of STAT transcription factors in oncogenic tyrosine kinase signaling. , 1998, Journal of biomedical science.

[31]  T. Hirano,et al.  STAT3 orchestrates contradictory signals in cytokine‐induced G1 to S cell‐cycle transition , 1998, The EMBO journal.

[32]  J. Darnell,et al.  Crystal Structure of a Tyrosine Phosphorylated STAT-1 Dimer Bound to DNA , 1998, Cell.

[33]  J. Darnell,et al.  Stat3 Activation Is Required for Cellular Transformation by v-src , 1998, Molecular and Cellular Biology.

[34]  R. Jove,et al.  STAT proteins as novel targets for cancer therapy. Signal transducer an activator of transcription. , 1999, Current opinion in oncology.

[35]  J. Darnell,et al.  Stat3 as an Oncogene , 1999, Cell.

[36]  T. Hirano,et al.  Synergistic roles for Pim-1 and c-Myc in STAT3-mediated cell cycle progression and antiapoptosis. , 1999, Immunity.

[37]  B. Löwenberg,et al.  STAT3-mediated differentiation and survival of myeloid cells in response to granulocyte colony-stimulating factor: role for the cyclin-dependent kinase inhibitor p27Kip1 , 2000, Oncogene.

[38]  Xiao-Rong Zeng,et al.  Regulation of Bcl-xL: a little bit of this and a little bit of STAT , 2000, Current opinion in oncology.

[39]  Simon C Watkins,et al.  Constitutive activation of Stat3 signaling abrogates apoptosis in squamous cell carcinogenesis in vivo. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[40]  Matthew B. Wilson,et al.  Control of myeloid differentiation and survival by Stats , 2000, Oncogene.

[41]  S. Akira.  Roles of STAT3 defined by tissue-specific gene targeting , 2000, Oncogene.

[42]  Roy Garcia,et al.  STATs in oncogenesis , 2000, Oncogene.

[43]  T. Hirano,et al.  Roles of STAT3 in mediating the cell growth, differentiation and survival signals relayed through the IL-6 family of cytokine receptors , 2000, Oncogene.

[44]  J. Turkson,et al.  Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression. , 2001, The Journal of clinical investigation.

[45]  J. Bromberg.  Activation of STAT proteins and growth control , 2001, BioEssays : news and reviews in molecular, cellular and developmental biology.

[46]  J. Turkson,et al.  Phosphotyrosyl Peptides Block Stat3-mediated DNA Binding Activity, Gene Regulation, and Cell Transformation* , 2001, The Journal of Biological Chemistry.

[47]  J. Nagpal,et al.  Activation of Stat‐3 as one of the early events in tobacco chewing‐mediated oral carcinogenesis , 2002, Cancer.

[48]  J. Pow-Sang,et al.  Constitutive activation of Stat3 in human prostate tumors and cell lines: direct inhibition of Stat3 signaling induces apoptosis of prostate cancer cells. , 2002, Cancer research.

[49]  L. Ellis,et al.  Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis , 2002, Oncogene.

[50]  N. Jing,et al.  Potassium-dependent folding: a key to intracellular delivery of G-quartet oligonucleotides as HIV inhibitors. , 2002, Biochemistry.

[51]  R. Jove,et al.  Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[52]  S. Cory,et al.  The Bcl2 family: regulators of the cellular life-or-death switch , 2002, Nature Reviews Cancer.

[53]  D. Coppola,et al.  Combination therapy with AG-490 and interleukin 12 achieves greater antitumor effects than either agent alone. , 2002, Molecular cancer therapeutics.

[54]  G. Feldman,et al.  Inhibition of STAT3 signaling induces apoptosis and decreases survivin expression in primary effusion lymphoma. , 2003, Blood.

[55]  David L Rimm,et al.  Tissue microarray analysis of signal transducers and activators of transcription 3 (Stat3) and phospho-Stat3 (Tyr705) in node-negative breast cancer shows nuclear localization is associated with a better prognosis. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[56]  Markus H. Heim,et al.  Characterization of Phosphopeptide Motifs Specific for the Src Homology 2 Domains of Signal Transducer and Activator of Transcription 1 (STAT1) and STAT3* , 2003, The Journal of Biological Chemistry.

[57]  A. Shiau,et al.  Constitutive activation of STAT3 and STAT5 is present in the majority of nasopharyngeal carcinoma and correlates with better prognosis , 2003, British Journal of Cancer.

[58]  N. Jing,et al.  Targeting Stat3 with G-quartet oligodeoxynucleotides in human cancer cells. , 2003, DNA and cell biology.

[59]  Huang Shao,et al.  Identification and characterization of signal transducer and activator of transcription 3 recruitment sites within the epidermal growth factor receptor. , 2003, Cancer research.

[60]  J. Grandis,et al.  Targeted inhibition of Stat3 with a decoy oligonucleotide abrogates head and neck cancer cell growth , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[61]  J. McMurray,et al.  Identification of a high-affinity phosphopeptide inhibitor of Stat3. , 2003, Bioorganic & medicinal chemistry letters.

[62]  D. Altieri.  Validating survivin as a cancer therapeutic target , 2003, Nature Reviews Cancer.

[63]  Nicola Gebbia,et al.  STAT proteins: From normal control of cellular events to tumorigenesis , 2003, Journal of cellular physiology.

[64]  C. Schindler,et al.  STATs Dimerize in the Absence of Phosphorylation* , 2003, Journal of Biological Chemistry.

[65]  J. Turkson,et al.  Discovery of JSI-124 (cucurbitacin I), a selective Janus kinase/signal transducer and activator of transcription 3 signaling pathway inhibitor with potent antitumor activity against human and murine cancer cells in mice. , 2003, Cancer research.

[66]  R. Cook,et al.  Structural Requirements for Signal Transducer and Activator of Transcription 3 Binding to Phosphotyrosine Ligands Containing the YXXQ Motif* , 2004, Journal of Biological Chemistry.

[67]  Chenguang Wang,et al.  Minireview: Cyclin D1: normal and abnormal functions. , 2004, Endocrinology.

[68]  N. Savaraj,et al.  G-quartet oligonucleotides: A new class of Stat3 inhibitors that suppresses growth of prostate and breast tumors through induction of apoptosis , 2004 .

[69]  N. Jing,et al.  G-Quartet Oligonucleotides , 2004, Cancer Research.

[70]  Weiguo Lu,et al.  VEGF, VEGFRs expressions and activated STATs in ovarian epithelial carcinoma. , 2004, Gynecologic oncology.

[71]  J. Clifford,et al.  Stat3 links activated keratinocytes and immunocytes required for development of psoriasis in a novel transgenic mouse model , 2005, Nature Medicine.